Teva Issues Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock Deal
July 27, 2015 6:03 AM EDTTeva Pharma (NYSE: TEVA) announced that it has signed a definitive agreement with Allergan plc (NYSE: AGN) to acquire Allergan Generics in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing an estimated under 10% ownership stake in Teva, with the number of Teva shares determined based on Tevas volume weighted average trading prices during the 15 days prior to the announcement and five days following the announcement. Teva believes the acquisition will be significantly accretive to... More
Teva Pharma (TEVA) Comments on Stichting's Move to Exercise Call Option on Mylan (MYL); Sees as 'Unwarranted'
July 23, 2015 9:06 AM EDTTeva Pharma (NYSE: TEVA) issued the following statement regarding Stichting Preferred Shares Mylans (Nasdaq: MYL) decision to exercise its call option:
We strongly disagree with the stated analysis of Stichting Preferred Shares Mylan and its decision... More
